D-serine in Schizophrenia

The Effects of Add-On D-serine Pharmacotherapy in Chronic Treatment Resistant Schizophrenia Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03702933

Acronym

DSRSZ

Enrollment

Registered

2018-10-11

Start date

2018-09-01

Completion date

2021-12-01

Last updated

2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Interventions

DIETARY_SUPPLEMENTD-serine

dosage

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items

Exclusion criteria

* clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior

Design outcomes

Primary

Measure	Time frame
PANSS Total Score	6 weeks

Countries

Israel

Contacts

Primary Contactandrea durrant, PhD

andy007israel@gmail.com972527181489

Backup ContactUriel Heresco-Levy, MD

urielh@ekmd.huji.ac.il97225316906

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026